All In Biotech

Drug Trial Radar · NCT04868877

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

194

Actual

Start

Apr 28, 2021

Primary completion

Oct 1, 2026

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Merus B.V.Industry
Sponsor type
Industry
First posted
May 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.

Conditions

  • Non-Small Cell Lung Cancer Metastatic
  • Gastric Cancer
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Colorectal Cancer

Interventions

  • MCLA-129Drug

    full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

  • OsimertinibDrug

    Approved, 3rd-generation EGFR-TKI

  • ChemotherapyDrug

    administrated by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)Time frame: First 28 days of treatment
  2. To evaluate clinical activity, as assessed by ORRTime frame: From first dose until RECIST progression or initiation of an alternative treatment, whichever occurs first.

Locations

51 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California, Irvine

    Orange, California

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • START Mountain Region

    West Valley City, Utah

  • Next Oncology Virginia

    Fairfax, Virginia

  • Institut Jules Bordet

    Anderlecht, Belgium

  • Antwerp University Hospital

    Edegem, Belgium

  • Clinique de l'Europe

    Amiens, France

  • CHU Hopitaux de Bordeaux - Hôpital Saint-André

    Bordeaux, France

  • CHU de Lyon - Louis Pradel Hospital

    Bron, France

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, France

  • Hôpital Albert Calmette

    Lille, France

  • L'Institut Paoli - Calmettes

    Marseille, France

  • CHU de Nantes - Hôpital Nord Laennec

    Nantes, France

  • Marie Wislez

    Paris, France

  • Hôpital Bichat - Claude-Bernard

    Paris, France

  • Hôpital Européen Georges Pompidou (HEGP)

    Paris, France

  • CHU de Poitiers

    Poitiers, France

  • Hôpital d'Instruction des Armées Bégin

    Saint-Mandé, France

  • Sana Klinikum Offenbach GmbH

    Offenbach, Germany

  • Krankenhaus Nordwest

    Frankfurt am Main, Hesse, Germany

  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi

    Bologna, Italy

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Azienda Ospedaliero - Universitaria San Luigi Gonzaga

    Orbassano, Italy

  • Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona

    Salerno, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento

    Verona, Italy

  • Istituto Nazionale dei Tumori Regina Elena

    Roma, Rome, Italy

  • Netherlands Cancer Institute

    Amsterdam, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • National Cancer Centre of Singapore

    Singapore, Singapore

  • Gachon University Gil Hospital

    Incheon, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital - Yonsei Cancer Center

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • The Catholic University of Korea, St. Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea

  • Hospital HM Delfos

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.